Empery Asset Management LP purchased a new position in Talphera, Inc. (NASDAQ:TLPH – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,333,497 shares of the company’s stock, valued at approximately $1,520,000. Talphera accounts for about 1.3% of Empery Asset Management LP’s investment portfolio, making the stock its 11th largest position. Empery Asset Management LP owned about 2.86% of Talphera at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Rosalind Advisors Inc. increased its stake in Talphera by 118.9% in the 3rd quarter. Rosalind Advisors Inc. now owns 4,385,757 shares of the company’s stock worth $3,917,000 after purchasing an additional 2,381,818 shares during the period. Nantahala Capital Management LLC increased its stake in Talphera by 75.3% in the 3rd quarter. Nantahala Capital Management LLC now owns 3,492,519 shares of the company’s stock worth $3,120,000 after purchasing an additional 1,500,000 shares during the period. Geode Capital Management LLC increased its stake in Talphera by 107.0% in the 4th quarter. Geode Capital Management LLC now owns 342,987 shares of the company’s stock worth $391,000 after purchasing an additional 177,294 shares during the period. Virtu Financial LLC purchased a new position in Talphera in the 3rd quarter worth approximately $29,000. Finally, Dauntless Investment Group LLC purchased a new position in Talphera in the 3rd quarter worth approximately $89,000. 37.67% of the stock is owned by hedge funds and other institutional investors.
Talphera Stock Performance
TLPH opened at $0.81 on Thursday. Talphera, Inc. has a 52-week low of $0.38 and a 52-week high of $1.57. The stock has a market capitalization of $41.95 million, a PE ratio of -2.61 and a beta of 0.76. The stock’s 50 day moving average price is $0.81 and its 200-day moving average price is $0.94.
Insider Activity
In other Talphera news, CEO Vincent J. Angotti bought 213,310 shares of Talphera stock in a transaction dated Friday, March 13th. The shares were purchased at an average cost of $0.59 per share, with a total value of $125,852.90. Following the completion of the purchase, the chief executive officer owned 800,705 shares of the company’s stock, valued at approximately $472,415.95. This represents a 36.31% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 3.50% of the company’s stock.
Analysts Set New Price Targets
A number of equities analysts have commented on the company. HC Wainwright assumed coverage on Talphera in a research note on Friday, June 5th. They issued a “buy” rating and a $3.00 price target on the stock. Westpark Capital assumed coverage on Talphera in a research note on Thursday, April 30th. They issued a “buy” rating and a $3.00 price target on the stock. Zacks Research raised Talphera to a “hold” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Talphera presently has a consensus rating of “Hold” and a consensus target price of $3.00.
Check Out Our Latest Stock Analysis on TLPH
Talphera Profile
Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.
See Also
- Five stocks we like better than Talphera
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Receive News & Ratings for Talphera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talphera and related companies with MarketBeat.com's FREE daily email newsletter.
